Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5506256 | 0.89 | HDAC3 (0.63) | HDAC3HDAC1HDAC2HDAC8SLC2A1 | |
| SCHEMBL6008774 | 0.81 | KIF11 (0.45) | HDAC3HDAC1HDAC2HDAC8SLC2A1 | |
| SCHEMBL5510239 | 0.81 | CNR2 (0.45) | HDAC3HDAC1HDAC2HDAC8SLC2A1 | |
| SCHEMBL6009935 | 0.79 | CHRM2 (0.66) | HDAC3HDAC1HDAC2HDAC8CHRM2 | |
| SCHEMBL355305 | 0.79 | CHRM2 (0.66) | HDAC3HDAC1HDAC2HDAC8SLC2A1 | |
| SCHEMBL5506450 | 0.78 | CHRM2 (0.42) | HDAC3HDAC1HDAC2HDAC8CHRM2 | |
| SCHEMBL5504090 | 0.77 | MPO (0.56) | CHRM2CYP2D6SCN8A | |
| SCHEMBL916840 | 0.77 | ADRB2 (0.47) | SLC2A1KCNH2 | |
| SCHEMBL918760 | 0.75 | KDM4E (0.68) | HDAC3HDAC1HDAC2HDAC8SLC2A1 | |
| SCHEMBL21171984 | 0.74 | NPY5R (0.64) | HDAC3HDAC1HDAC2HDAC8SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828111-A2 | METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | US | disclosed |
| WO-2006059252-A2 | METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | APP, PSEN1, TTR | HDAC3 3990/4885HDAC1 4260/4885HDAC2 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.